Product Images Xarelto

This is a medication called Ivaroxaban, which is also known as Xarelto. The bottle contains 1800 tablets of 10 milligrams each with a National Drug Code (NDC) number of 71610-0690-42. The other information appears to be illegible or not available.*

This is a table of data with percentages related to patient characteristics, such as prior use of warfarin, age, gender, weight, diabetes status, CHADS2 score, geographic region, ASA use at randomization, and treatment with either rivaroxaban or warfarin. It also includes hazard ratio and 95% confidence intervals related to favoring treatment with rivaroxaban over warfarin. No further information or context is available.*

This text contains pharmacokinetic (PK) information for the drug rivaroxaban in different populations. It provides fold change and 90% confidence interval for the PK parameters Cmax and AUC post dose. The populations evaluated include those with end-stage renal disease (ESRD), renal impairment, variations in age and body weight, and hepatic impairment. The results are specific to those with creatinine clearance levels ranging from severe to normal, and the ESRD data represents subjects maintained with chronic and stable hemodialysis.*

This is a table of drug interactions and their effect on the pharmacokinetics (PK) of different drugs, specifically their maximum concentration (Cmax) and area under the concentration-time curve (AUC). The first section refers to combined inhibitors of the P-glycoprotein (P-gp) transporter and the CYP3A enzyme, while the second section refers to moderate CYP3A inhibitors and other drugs. The last row shows the fold change in the PK parameters compared to the drug rivaroxaban alone.*

This appears to be a statistical table providing data on the effectiveness of XARELTO in comparison to placebo across different age groups, weight range, and medical history. The efficacy of XARELTO was measured by a composite outcome of stroke and death from cardiovascular causes. The table also includes data on the characteristics of the study population, including age, sex, geographical location, weight range, and medical history of heart attack, diabetes, and heart-taker.*

This appears to be a graph showing the cumulative incidence rate of XARELTO versus a placebo over a period of 1095 days from randomization. The graph shows the percentage of subjects at risk and the number of subjects at risk. The vertical axis shows the cumulative incidence rate in percentage while the horizontal axis shows the number of days from randomization.*

The text provided seems to be a table presenting data on Cumulative Incidence Rate (%) for a comparison between XARELTO and Placebo. The table divides the data into two treatment groups and presents a comparison under "Hazard Ratio (55% C)." The table includes data related to the number of subjects at risk and days from randomization. No additional information is available to provide a more detailed description.*

Not available.*

The text is not-available because there is not enough information to generate a useful description.*

This text is a prompt to check and mark the expiration date of a product with the message "Discard after".*

This text appears to be a table or list showing various measurements in milliliters (mL) and the composition of each measurement in terms of smaller volumes of 5mL. Without further context, it is difficult to determine what the purpose or meaning of this information is.*